NCT05957367 2026-03-06
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT05734105 2025-12-17
INSIGHT
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT04633122 2025-02-10
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT04530981 2024-09-19
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT06507683 2024-07-18
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
First Affiliated Hospital of Chongqing Medical University
Phase NA Recruiting
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT03353753 2022-11-21
INVICTUS
Deciphera Pharmaceuticals, LLC
Phase 3 Completed
NCT05080621 2022-01-05
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2 Withdrawn